SLC5A2 and type 2 diabetes mellitus: This meta-analysis of six large-scale RCTs, enrolling a combined total of 47,411 patients with T2DM, demonstrated that SGLT2 inhibitors significantly reduced the risk of HHF by 28% compared with placebo or standard care (RR: 0.72, 95% CI: 0.65-0.80; p<0.00001).